Bernard Zovighian - Edwards Lifesciences President
EW Stock | USD 95.56 0.41 0.43% |
President
Mr. Bernard J. Zovighian was Corporationrationrate Vice President Surgical Heart Valve Therapy since January 2016. He joined Edwards in January 2015 as Vice President and General Manager for the surgical heart valve business. Prior to joining Edwards, Mr. Zovighian held a variety of roles with increasing levels of responsibility at Johnson Johnson for nearly 20 years, including Worldwide President of Advanced Sterilization Products from 2011 to 2014, and President of JJMP, Johnson Johnson medical technology business in Canada, from 2006 to 2011. Mr. Zovighian has extensive senior leadership experience in the medical device industry in Europe and North America. He has held roles of increasing responsibility in sales, marketing, business development, general management and commercial introduction and adoption of disruptive technology that has elevated the standard of care since 2016.
Age | 56 |
Tenure | 8 years |
Professional Marks | MBA |
Address | One Edwards Way, Irvine, CA, United States, 92614 |
Phone | 949 250 2500 |
Web | https://www.edwards.com |
Bernard Zovighian Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bernard Zovighian against Edwards Lifesciences stock is an integral part of due diligence when investing in Edwards Lifesciences. Bernard Zovighian insider activity provides valuable insight into whether Edwards Lifesciences is net buyers or sellers over its current business cycle. Note, Edwards Lifesciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Edwards Lifesciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bernard Zovighian over three months ago Discretionary transaction by Bernard Zovighian of 2558 shares of Edwards Lifesciences subject to Rule 16b-3 |
Edwards Lifesciences Management Efficiency
The company has Return on Asset (ROA) of 0.1225 % which means that for every $100 of assets, it generated a profit of $0.1225. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.2234 %, which means that it produced $0.2234 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to drop to 0.14 in 2024. Return On Assets is likely to drop to 0.08 in 2024. At this time, Edwards Lifesciences' Fixed Asset Turnover is fairly stable compared to the past year. Asset Turnover is likely to climb to 0.80 in 2024, whereas Return On Assets are likely to drop 0.08 in 2024.Similar Executives
Found 13 records | PRESIDENT Age | ||
Andrew Balo | DexCom Inc | 76 | |
John Lister | DexCom Inc | 40 | |
Lanny Roper | DexCom Inc | 50 | |
Menashe Sonnenschein | Medigus Ltd ADR | 48 | |
Jeffrey Moy | DexCom Inc | 57 | |
Hemanth CFA | Venus Concept | 48 | |
Jake Leach | DexCom Inc | 40 | |
Patrick Murphy | DexCom Inc | 39 | |
Heather Ace | DexCom Inc | 48 | |
Yaron Zilberman | Medigus Ltd ADR | 42 | |
Donald Abbey | DexCom Inc | 51 | |
Richard Doubleday | DexCom Inc | 55 | |
Benjamin CFA | Monogram Orthopaedics Common | 40 |
Management Performance
Return On Equity | 0.22 | ||||
Return On Asset | 0.12 |
Edwards Lifesciences Corp Leadership Team
Elected by the shareholders, the Edwards Lifesciences' board of directors comprises two types of representatives: Edwards Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edwards. The board's role is to monitor Edwards Lifesciences' management team and ensure that shareholders' interests are well served. Edwards Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edwards Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Paul LaViolette, Independent Director | ||
John Cardis, Independent Director | ||
Wesley Schack, Presiding Independent Director | ||
Larry Wood, Corporate Vice President - Transcatheter Aortic Valve Replacement | ||
Leslie Heisz, Independent Director | ||
Catherine Szyman, Corporate Vice President - Critical Care | ||
Arnold Pinkston, Corporate Counsel | ||
Barbara McNeil, Independent Director | ||
Steven Loranger, Independent Director | ||
Scott Ullem, Chief Financial Officer, Corporate Vice President | ||
Patrick Verguet, Corporate VP of EMEA, Canada and Latin America | ||
Kieran Gallahue, Independent Director | ||
Nicholas Valeriani, Independent Director | ||
Heisz Stone, Independent Director | ||
Mark Wilterding, Vice Relations | ||
MD FACC, Corporate Officer | ||
Martha Marsh, Lead Independent Director | ||
Daveen Chopra, Corporate Vice President - Surgical Structural Heart | ||
Huimin Wang, Corporate Vice President - Japan, Asia and Pacific | ||
JeanLuc Lemercier, Corporate Vice President - EMEA (Europe, Middle East and Africa) | ||
Christine McCauley, Corporate Resources | ||
William Link, Independent Director | ||
Ramona Sequeira, Independent Director | ||
Bernard Zovighian, Corporate Vice President -Surgical Heart Valve Therapy | ||
David Erickson, Vice President - Investor Relations | ||
Donald Bobo, Corporate Vice President - Strategy and Corporate Development | ||
Todd Brinton, Co Officer | ||
Dirksen Lehman, Corporate Affairs | ||
Michael Mussallem, Chairman of the Board, Chief Executive Officer |
Edwards Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edwards Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.22 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.23 % | ||||
Operating Margin | 0.39 % | ||||
Current Valuation | 56.57 B | ||||
Shares Outstanding | 601.3 M | ||||
Shares Owned By Insiders | 0.88 % | ||||
Shares Owned By Institutions | 83.60 % | ||||
Number Of Shares Shorted | 10.45 M | ||||
Price To Earning | 32.77 X |
Edwards Lifesciences Investors Sentiment
The influence of Edwards Lifesciences' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Edwards. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Edwards Lifesciences' public news can be used to forecast risks associated with an investment in Edwards. The trend in average sentiment can be used to explain how an investor holding Edwards can time the market purely based on public headlines and social activities around Edwards Lifesciences Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Edwards Lifesciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Edwards Lifesciences' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Edwards Lifesciences' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Edwards Lifesciences.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Edwards Lifesciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Edwards Lifesciences' short interest history, or implied volatility extrapolated from Edwards Lifesciences options trading.
Pair Trading with Edwards Lifesciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edwards Lifesciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edwards Lifesciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Edwards Stock
0.89 | BSX | Boston Scientific Corp Financial Report 24th of April 2024 | PairCorr |
0.68 | COO | Cooper Companies Financial Report 6th of June 2024 | PairCorr |
Moving against Edwards Stock
0.86 | MCRB | Seres Therapeutics Financial Report 14th of May 2024 | PairCorr |
0.81 | PHG | Koninklijke Philips Financial Report 22nd of April 2024 | PairCorr |
0.73 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
0.71 | PIIIW | P3 Health Partners | PairCorr |
0.69 | TFX | Teleflex Incorporated Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Edwards Lifesciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edwards Lifesciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edwards Lifesciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edwards Lifesciences Corp to buy it.
The correlation of Edwards Lifesciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edwards Lifesciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edwards Lifesciences Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edwards Lifesciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edwards Lifesciences Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Edwards Stock analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Edwards Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edwards Lifesciences. If investors know Edwards will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edwards Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 2.31 | Revenue Per Share 9.897 | Quarterly Revenue Growth 0.138 | Return On Assets 0.1225 |
The market value of Edwards Lifesciences Corp is measured differently than its book value, which is the value of Edwards that is recorded on the company's balance sheet. Investors also form their own opinion of Edwards Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Edwards Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edwards Lifesciences' market value can be influenced by many factors that don't directly affect Edwards Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edwards Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edwards Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edwards Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.